Expert Advisory Panel on Trasylol^® (aprotinin)

Health Canada uses ad hoc scientific/experts advisory panels to provide medical/technical/scientific advice and recommendations on issues related to health products.

The Expert Advisory Panel on Trasylol^® (EAP-Trasylol^®) was held in Ottawa, Ontario on December 3, 2008 and January 29, 2009 to discuss benefit/risk issues relating to Trasylol^® (aprotinin). The EAP-Trasylol^® was requested to address the following questions regarding the use of Trasylol^® (aprotinin);

• in current cardiac surgery;
• the relevance of the clinical trials at the time of approval in 1995 to current Coronary Artery Bypass Graft (CABG) surgery;
• the relevance of the BART study; and
• the benefit/risk balance of Trasylol^® in current cardiac surgery.

The members of the Expert Advisory Panel on Trasylol^® were appointed by Health Canada through a call nomination system.

• Terms of Reference of the Expert Advisory Panel on Trasylol^®
• Summary of Expertise, Experience, Affiliations and Interests for the Expert Advisory Panel on Trasylol^®
• Summary Report - Expert Advisory Panel on Trasylol^®
• Final Report - Expert Advisory Panel on Trasylol^®

Related Information

• Health Canada's Decision on Trasylol^®(aprotinin)

For more information on the Expert Advisory Panel on Trasylol^®, contact the Marketed Health Products Directorate.